Lakefront Biotherapeutics (LKFT) EBIT Margin (2014 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly EBIT Margin of 982.92% for Q1 2026, down 77124.0% year-on-year from N/an in Q1 2025, and down 1269.36% on a QoQ basis from 84.06% in Q4 2025.
Lakefront Biotherapeutics (LKFT) EBIT Margin (2014 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported EBIT Margin for 13 consecutive years, with 982.92% the latest figure, recorded in Q1 2026.
- Quarterly EBIT Margin fell 77124.0% year-over-year to 982.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 37.37% (up 11761.0% YoY) and the FY2025 annual result came in at 26.53%, up 9485.0% from the prior year.
- EBIT Margin declined to 982.92% in Q1 2026 per LKFT's latest filing, from 84.06% in the prior quarter.
- Over the last five years, EBIT Margin for LKFT reached as high as 620.0% in Q4 2024 and fell as low as 982.92% in Q1 2026.
- A 5-year average of 105.03% and a median of 53.07% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2022 — EBIT Margin soared 273065 bps — and 2026, when it plunged 77124 bps.
- Year by year, EBIT Margin stood at 2.21% in 2022, then jumped by 8644 bps to 193.5% in 2023, then jumped by 220 bps to 620.0% in 2024, then slumped by 86 bps to 84.06% in 2025, then tumbled by 1269 bps to 982.92% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 982.92%, 84.06%, and 647.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Lakefront Biotherapeutics | 1.85 Bn | -1.64 Bn | 1.91 Mn | -982.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -982.92% |
| Dec 31, 2025 | 84.06% |
| Sep 30, 2025 | -647.30% |
| Jun 30, 2025 | 240.73% |
| Mar 31, 2025 | -211.68% |
| Dec 31, 2024 | 620.00% |
| Sep 30, 2024 | -102.66% |
| Jun 30, 2024 | -198.22% |
| Mar 31, 2024 | -53.07% |
| Dec 31, 2023 | 193.50% |
| Sep 30, 2023 | -23.23% |
| Jun 30, 2023 | -22.49% |
| Mar 31, 2023 | -24.24% |
| Dec 31, 2022 | 2.21% |
| Sep 30, 2022 | -149.68% |
| Jun 30, 2022 | -363.78% |
| Mar 31, 2022 | -146.74% |
| Dec 31, 2021 | 1.81% |
| Sep 30, 2021 | -2,880.33% |
| Jun 30, 2021 | -33.45% |